Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002049 | 0.91 | TDP1 (0.44) | TDP1ALDH1A1LMNASIRT6KMT2A | |
| SCHEMBL8113298 | 0.87 | HSD17B1 (0.37) | HSD17B1TDP1ALDH1A1LMNASIRT6 | |
| SCHEMBL7000772 | 0.85 | TDP1 (0.44) | TDP1ALDH1A1LMNASIRT6KMT2A | |
| SCHEMBL424613 | 0.81 | HSD17B1 (0.54) | HSD17B1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL1025994 | 0.80 | KMT2A (0.44) | HSD17B1ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL20214438 | 0.80 | KMT2A (0.58) | TDP1ALDH1A1LMNASIRT6KMT2A | |
| SCHEMBL9621112 | 0.77 | KMT2A (0.53) | HSD17B1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL9621080 | 0.77 | KMT2A (0.53) | HSD17B1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2205282 | 0.77 | MEN1 (0.48) | TDP1ALDH1A1LMNASIRT6KMT2A | |
| SCHEMBL25276892 | 0.77 | MAPT (0.49) | HSD17B1ALDH1A1KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104242-A1 | 4-(2-AMINO-TETRAHYDRONAPHTHALENYL)PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1263763-B1 | TUBULIN BINDING LIGANDS | UNIV BAYLOR (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1263763-B1 | TUBULIN BINDING LIGANDS | UNIV BAYLOR (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060142252-A1 | Tubulin binding agents and corresponding prodrug constructs | PINNEY KEVIN G | 2006-06-29 | — | — | US | disclosed |
| US-7001926-B2 | Tubulin binding agents and corresponding prodrug constructs | OXIGENE, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040043969-A1 | Tubulin binding agents and corresponding prodrug constructs | MATEON THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6593374-B2 | Such as 3-(3'4'5'-trimethoxybenzoyl)-2-(3'benzylphosphate 4'methoxyphenyl)-6-methoxybenzo(b)thiophene; functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates useful as antitumor agents | BAYLOR UNIVERSITY | 2003-07-15 | — | — | US | disclosed |
| EP-1263763-A2 | TUBULIN BINDING LIGANDS AND CORRESPONDING PRODRUG CONSTRUCTS | BAYLOR UNIVERSITY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020055643-A1 | Tubulin binding ligands and corresponding prodrug constructs | MATEON THERAPEUTICS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| WO-2001068654-A2 | TUBULIN BINDING LIGANDS AND CORRESPONDING PRODRUG CONSTRUCTS | BAYLOR UNIVERSITY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043969-A1 | Tubulin binding agents and corresponding prodrug constructs | TUBB4A, TUBB3, TUBB | HSD17B1 4441/4885TDP1 783/4885ALDH1A1 3346/4885 |
| US-20180104242-A1 | 4-(2-AMINO-TETRAHYDRONAPHTHALENYL)PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | HSD17B1 4229/4885TDP1 934/4885ALDH1A1 950/4885 |
| US-20020055643-A1 | Tubulin binding ligands and corresponding prodrug constructs | TUBB, TUBB3, TUBB4A | HSD17B1 4249/4885TDP1 848/4885ALDH1A1 3462/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | HSD17B1 2190/4885TDP1 4245/4885ALDH1A1 180/4885 |
| US-20060142252-A1 | Tubulin binding agents and corresponding prodrug constructs | TUBB4A, TUBB3, TUBB | HSD17B1 4441/4885TDP1 783/4885ALDH1A1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.